Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Natural History Study in Patients With LGMDR5/2c
- Conditions
- Gamma-sarcoglycanopathy
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Atamyo Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT06210672
- Locations
- 🇫🇷
Hopital Raymond Poincare, Garches, France
🇹🇳Hedi Chaker Hospital Child Neurology Department, Sfax, Tunisia
🇹🇳National Institute Mongi Ben Hmida of Neurology, Tunis, Tunisia
ATA-200 Dose-escalation Gene Therapy Trial in Patients With LGMDR5
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Atamyo Therapeutics
- Target Recruit Count
- 6
- Registration Number
- NCT05973630
- Locations
- 🇺🇸
Child Health Research Institute, Gainsville, Florida, United States
🇫🇷Hopital Trousseau, Paris, France
🇮🇹Ospedale Maggiore Policlinico, Milano, Italy
GNT0006 Gene Therapy Trial in Patients With LGMDR9
- Conditions
- LGMDR9
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Atamyo Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT05224505
- Locations
- 🇩🇰
Rigshospitalet, University of Copenhagen Blegdamsvej 9, Copenhagen, Denmark
🇫🇷Institute of Myology Pitié-Salpêtrière Hospital 47 Bd de l'Hôpital, Paris, France
🇬🇧Royal Victoria Infirmary Queen Victoria Road Level 6 Leazes Wing, Newcastle Upon Tyne, United Kingdom
News
Atamyo Therapeutics' ATA-200 Gene Therapy Receives FDA Clearance for US Clinical Trial in LGMD2C/R5
The FDA has cleared Atamyo Therapeutics' IND application for ATA-200, a gene therapy for Limb-Girdle Muscular Dystrophy Type 2C/R5 (LGMD2C/R5).
FDA Clears Atamyo's ATA-200 Gene Therapy Trial for LGMD2C/R5 in Children
The FDA has approved Atamyo Therapeutics' Investigational New Drug application for ATA-200, a gene therapy for limb-girdle muscular dystrophy type 2C/R5 (LGMD2C/R5).
FDA Approves Autolus' Obecabtagene Autoleucel (Aucatzyl) for R/R B-cell ALL
• The FDA has approved obecabtagene autoleucel (obe-cel), a CD19-directed CAR-T therapy, for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-cell ALL). • Approval was based on the Phase 1b/2 FELIX trial, which demonstrated overall complete remission rates above 60% and durable remissions exceeding 12 months. • Clinical holds on CARsgen's BCMA-directed CAR-T therapy zevorcabtagene autoleucel and Claudin18.2-directed CAR-T satricabtagene autoleucel have been removed by the FDA.
Atamyo Therapeutics Advances Gene Therapy Programs for Limb-Girdle Muscular Dystrophy
Atamyo Therapeutics completed recruitment for the dose escalation phase of the Phase 1b trial of ATA-100 for LGMD2I/R9.